saw underli sale growth cer ep growth
ahead consensu dupix sale strong even allow
gross net adjust posit inventori move vaccin
benefit easi comp new chines tender process
limit impact sale cfo talk chang mind set
cost reiter trajectori op exp growth
strong sale result tighten guidanc top end
ep rang john reed head highlight recent data
number asset reiter focu in-hous rather partner
drug time reduc relianc dupix despit strong
credenti new head new cfo investor like
want check strateg direct set new ceo paul
hudson want continu develop current busi unit
sanofi increas focu see return increment
invest could potenti disrupt strong cost control
sutimlimab data agglutinin diseas new ceo paul hudson
strategi updat dupi ad children data key risk us
healthcar reform diabet drug particularli focu
valuat sanofi trade price-to-earnings discount
global peer ev/npv sanofi trade discount
global peer cheapest global major metric
valuat metric
price-to-earnings rel local market
number share
price month
price rel chart measur perform
close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
sanofi-aventi pharmaceut group engag research
develop manufactur market healthcar product
vaccin sanofi pasteur
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
blue sky scenario assum full pipelin success stronger
growth rate diabet
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
grey sky assum pipelin success greater declin
diabet driven greater gener competit lantu poor
uptak lixilan
price rel chart measur perform
close
spot exchang rate
charl martineau pm univers toronto cs view sale growth margin
figur sale growth busi oper margin
chang forecast
made limit chang number rais ep
figur chang forecast
diabet annual declin cs
sg sale
buy back cs
major product sale
gm impact
donut hole extra spend
yr
cer
turn profit
buy-back focu
debt reduct acq
n/c note chang mind
set cost
profit
ep growth weight
chang
envelop
manag
figur eu us major pharma compar valuat
sanofi premium/ discount eu
sanofi premium/ discount global
sanofi result commentari
compani sale cer cer constant structur
rais guidanc upper rang previou guidanc
china em
blood assist cablivi launch off-set on-going competit pressur us
eloct
immunolog dupix annual due asthma launch strong ad uptak
oncolog strong growth china portfolio transit toward spec care
ms increas aubagio sale despit competitor launch
diseas dd perform core franchis
dd growth new patient start specialist
deeper hcp penetr ad prescrib written rx
dupix patient new biolog
crswnp launch way
growth vaccin larg due continu recoveri pentaxim china
month delay strain select impact time flu deliveri sale
signific weight opposit
injunct praluent sale germani follow patent rule
establish product
solid growth em off-set us sale
admelog light futur qs due wac price adjust
us eu
growth rate moder non-strateg brand divest offset solid perform
emerg market cer
asia china
largest market us
growth driven vaccin spec care
volum base procur problem impact plavix aprovel larg citi
may sanofi product recent list nmpa medicin urgent need includ
dupix product submiss plan end
dupix adolesc ad nasal polyp eu
isatuximab eu us
menquadfi us
fluzon us eu
sutimlimab agglutinin diseas
dupix ad children
olipudas alfa acid sphingomyelinas defici
avalglucosidas alfa pomp diseas
serd bc
sutimlimab refractori immun thrombocytopen purpura
adult copd
posit fx impact sale
improv boi despit op expens mab collabor reach break-even
expect profit
 expens due late stage pipelin invest
impair due eloct
gross margin increas
expect keep opex fy
fx impact busi ep
vision continu effort reshap portfolio increas innov invest best-in-
strategi focu diseas high unmet medic need
total number project higher due higher organ growth alnylam acquisit
develop research project
dev project spec care vaccin
refocu cv diabet research
realloc resourc biolog gene therapi
fill head develop posit
expand verili digit partnership acceler recruit rwe
partnership cegedim world data
submiss next year sanofi-own asset
high proport asset first best-in-class
icariamm eha first trial show prolong went ad
ab ad soc
median vs soc
benefit consist across popul
first studi show revers renal dysfunct
need post infus medic well toler
visit hospit still necessari subcut administr still need sig hospit
time lack need post-infus medicin
think competit r/r set approv
bind differ epitop competitor could still show superior effect competitor
reduc abil activ complement henc better toler
diseas control rate
toler grade higher seen patient neutropenia
aim new soc nsq-nsclc
registr studi start year end
fitusiran neutropenia
hemophilia without inhibitor
atla on-going plan submit
breadth usag
stabl room temp
antidot avail market revers requir
bleed episod success treat low dose bpa
use rnai regul anti-thrombin restor coagul
fusion protein vw factor
first overcom vwf ceil limit current treatment
subject develop inhibitor fviii
regular monitori necessari stabl pharmacolog
initi
children expect infect rsv age two
fda breakthrough design prime eu
focu biolog increas innov
support transform enhanc digit platform gene therapi biolog
posit data prioriti program blood disord oncolog vaccin
rich news flow clinic data expect next month
improv growth profil extend
opex growth
acceler growth contribut dupix
 dupix grow ahead rx qoq stock rebat benefit
driver favor growth net driven demand gross net patient
finish co-pay report reflect posit yoy driven demand first price
increas juli jan inventori vs last year
inventori fluctuat expect
 strong poc isth start dose weekli dose
havent reach final decis dose dose effect week although
consist intern debat on-going dose phase start
intent explor dose point
 show strong gross margin opex line guidanc despit
invest detail fruit initi cost manag confirm line
intern target set
driver impact us china pretti high kick
guidanc rais cog room improv sg help maintain
growth margin sg late stage roll-out mani opportun reinvest
fuel growth keep growth opex chang mindset cash sanofi
 dupix posit give breakdown ad asthma us
sequenti growth global year-over-year contribut
asthma new indic geographi realli momentum across
whole product strong growth around indic broken
quarter-on-quart br growth overal driven derm
allergen would expect littl bit higher growth rate
pulmonologist sinc launch asthma go break mix allergist due
 haemophilia share view busi perform expect
took impair charg eloct greater expect market loss hemlibra
believ non-inhibitor market expect slower market infiltr hemlibra histor
sticki safeti consciou market look ahead expect competit pressur continu
point differenti eloct big advantag joint health immun
toler induct plan potenti launch addit market latam asia
eloct foundat franchis expect industry-lead franchis beyond
haemophilia sutilimab cad itp also follow eloct
stronger profil earli gene therapi program bioverativ strong pipelin
 consum perform emerg softer could done re-energ
busi europ
emerg market quit strong flat lower perform
due cough cold season off-set price increas argentina continu
strong growth china eurasia south east asia expect strong growth em
europ affect season divest tighten regulatori environ
also impact europ ich guidelin withdraw older product franc
 posit serd asset given timing/dur adjuv
focu combin move metastat breast cancer set
success gear studi test move adjuv stick
timelin
 lot movement nsclc see posit
attract nsclc patient receiv io limit option
chemo cyramza ae/efficaci leav much desir first studi
vs doxa ph combin cyramza timelin possibl bring forward
faster meet fda next month conserv estim
 durabl respons seen
evalu still on-going sure met median dor still collect data
encourag diseas control addit orr
 eloxatin futur pressur china think futur pressur
offici commun futur impact
 praluent updat us litig view compensatori damag
would share regeneron
feb claim valid split decis hear yet rule busi
continu usual us file post trial motion court request oral argument
schedul august specul long continu issu
damag address prematur comment
 expect avalglucosidas alfa acceler growth pomp franchis
excit product gen discov in-hous research hope
product better myozym preclin show high uptak myozym
invivo show superior assum cannib myozym
 regeneron payment oper incom
includ share mab allianc net market expens incur regeneron
increas vs posit break even expect profit
acceler growth dupix mean alreadi break even half grow
neg link success partnership
 us reform remov penni rule medicaid aml cap impact remov rule
would sanofi
oppos littl improv larg major patient move target noth
final cap sever version consid remov cap
latest awar suggest modif max rebat cap howev
kick pair launch year price appli retrospect dont feel
appli lantu prospect care price increas
potenti cpi impact medicaid
 dupix ex-u adopt europ price europ add increment
similar uptak everi launch countri compar seem uptak vs cosentyx
launch alway thought price multi indic product downward
pressur result taken consider tri mitig
 praluent indic sale due rebat volum prior period
grow nice us expand label nbrx grow price pressur off-set
volum growth noth unusu go forward see volum transcend
 opex growth indic growth come year prior friday zynquista
remov zynquista launch posit next year growth extra opportun
fuel growth area busi
 elabor expect copd data hous progress
expect subset patient type inflamm studi test
studi compar combin better insight cytokin
relev copd on-going studi standard level success wait
 feedback cablivi launch track far
pleas initi demand de austria us launch far build market
scratch innov therapi take time track well market feedback
gbu diabet cardiovascular ex em
number share outstand fd
busi ep fd
compani mention price
